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Abstract
Background: Tinnitus is a result of hyper-activity/hyper-synchrony of auditory neurons coding the tinnitus
frequency, which has developed due to synchronous mass activity owing to the lack of inhibition. We assume that
removal of exactly these frequencies from a complex auditory stimulus will cause the brain to reorganize around
tonotopic regions coding the tinnitus frequency through inhibition-induced plasticity. Based on this assumption,
a novel treatment for tonal tinnitus - tailor-made notched music training (TMNMT) - has been introduced and was
tested in this clinical trial.
Methods: A randomized controlled trial in parallel group design was performed in a double-blinded manner. We
included 100 participants with chronic, tonal tinnitus who listened to tailor-made notched music for two hours a
day for three consecutive months. Our primary outcome measures were the Tinnitus Handicap Questionnaire and
Visual Analog Scales measuring perceived tinnitus loudness, awareness, distress and handicap. Participants rated
their tinnitus before and after the training as well as one month after cessation of the training.
Results: While no effect was found for the primary outcome measures, tinnitus distress, as measured by the
Tinnitus Questionnaire, a secondary outcome measure, developed differently in the two groups. The treatment
group showed higher distress scores while the placebo group revealed lower distress scores after the training.
However, this effect did not reach significance in post-hoc analysis and disappeared at follow-up measurements.
At follow-up, tinnitus loudness in the treatment group was significantly reduced as compared to the control group.
Post hoc analysis, accounting for low reliability scores in the Visual Analog Scales, showed a significant reduction of
the overall Visual Analog Scale mean score in the treatment group even at the post measurement.
Conclusion: This is the first study on TMNMT that was planned and conducted following the CONSORT
statement standards for clinical trials. The current work is one more step towards a final evaluation of TMNMT.
Already after three months the effect of training with tailor-made notched music is observable in the most
direct rating of tinnitus perception – the tinnitus loudness, while more global measures of tinnitus distress do
not show relevant changes.
Trial registration: Current Controlled Trials ISRCTN04840953; Trial registration date: 17.07.2013
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Background
Tinnitus is a phantom perception that is a chronic con-
dition in 10 to 15 % of the general population [1]. While
some manage to cope with tinnitus, not everyone com-
pensates it equally. Tinnitus is often accompanied by
sleeping problems, stress and depression and can result
in a significant reduction in quality of life [2]. Besides in-
dividual impairment, the economic burden caused by
tinnitus is also a substantial issue [3]. Many attempts
have been made to treat or even cure tinnitus, yet no
treatment or intervention offers a completely satisfactory
solution. This might be due to the fact that the exact
neurophysiological mechanism underlying tinnitus is still
not thoroughly understood.
Studies of noise-induced tinnitus have given rise to the
general theory that tinnitus is triggered by injury to
inner ear hair cell populations [4]. Damage to these cell
populations results in reduced activation in the auditory
nerve and reduced input to the auditory cortex [5]. The
result is not only a loss of excitation of neurons coding
the hearing loss region in the auditory cortex, but also a
loss of inhibition from the primarily damaged frequency
areas [6]. This triggers maladaptive plastic adjustments
in the central auditory system, which culminate in
maladaptive functional reorganization and alterations
of spontaneous brain activity. As a result, neurons
coding the frequencies at the audiometric edge be-
come over-represented. This hyperactivity resembles
the tinnitus perception caused by a lack of inhibition.
While the neural generators may be primarily auditory
cortical areas, non-auditory regions also play a crucial
role [7–10], resulting in maladaptive attention towards
tinnitus, as well as an aversive emotional response.
Many existing tinnitus treatments include specific
auditory stimulation to induce changes in auditory pro-
cessing that may reduce the tinnitus percept. These very
heterogenic treatment strategies are subsumed under the
term “sound therapies” and can differ with regard to the
targeted mechanism like masking, habituation, residual
inhibition, neuro-modulation or a combination of these
methods [5, 6]. In the sound therapies focusing on
masking, the tinnitus is continuously covered with an-
other sound stimulus (e.g., white noise) which can dis-
tract subjects from their tinnitus [7]. Partial masking is
part of the tinnitus retraining therapy [11] that is sup-
posed to allow habituation to tinnitus. Yet, it is not clear
whether there is a specific effect of the acoustic stimula-
tion in TRT [12]. Nevertheless, supra-threshold masking
can suppress tinnitus entirely in some tinnitus subjects,
a phenomenon called residual inhibition [13]. However,
this only lasts for seconds or minutes until the tinnitus
recovers to its previous loudness. In the approaches fo-
cusing on neuro-modulation, specific sets of sounds are
used to target the neural activity, which is assumed to
underlie the sensation of the tinnitus. In one approach,
tones with different frequencies around the tinnitus fre-
quency are used in a specific rhythm to desynchronize
tinnitus-related neuronal activity [14, 15]. However, the
effectiveness of the latter remains unclear, as up to now
there is no randomized clinical trial investigating this
treatment strategy. So far, reviews concerning sound
therapies found rather small effect sizes or no effects at
all [5, 6, 8]. However, it remains unclear whether these
results can be attributed to the lack of quality in re-
search focusing on the effect of sound therapies without
any additional counseling, or the small effect sizes of the
treatment strategies per se [5, 8].
To contribute to the research on sound therapies against
tinnitus, this study aims at evaluating the specific effect of a
sound therapy focusing on induced inhibition, namely the
tailor-made notched music training (TMNMT), which is
described in detail below.
Inhibition, mainly lateral inhibition, can be evoked by
presenting band-eliminated sounds to the auditory
system [16]. The removal of a frequency band from an
auditory stimulus will cause the brain to reorganize
around tonotopic regions coding the frequencies within
the band. Based on this assumption, a novel treatment
for tonal tinnitus has been introduced and evaluated in a
previous study: the tailor-made notched music training
(TMNMT) [17]. During the course of 12 months, for 1
to 2 h per day, participants listened to music from which
the spectral energy band of one octave around their indi-
vidual tinnitus frequency had been removed. The hy-
pothesis was that while auditory cortex neurons coding
the tinnitus frequency would not get any or small affer-
ent input, neighboring neurons would be activated and
would inhibit the frequencies within the notch via lateral
inhibition [16]. Okamoto et al. [17] chose the partici-
pants’ favorite music as the auditory stimulus for two
reasons: music as an acoustic carrier of the treatment
method has a sufficiently wide energy spectrum, includ-
ing the tinnitus frequency; and the favorite music is able
to increase positive attention that facilitates brain func-
tional reorganization. TMNMT has been proved to re-
duce auditory evoked cortex activity measured by means
of magnetoencephalography specifically for the tinnitus
frequency [17]. Furthermore, behavioral change was
monitored via Visual Analog Scales (VAS). Partici-
pants reported a reduction of the tinnitus loudness
after the training. These effects were superior to any
changes in the placebo or monitoring group after
12 months of TMNMT. After 6 month there was a re-
duction in loudness in the target group, however, this
effect was not compared with the effect in the placebo
or the monitoring group. A subsequent short-term
concentrated (5 days, 6 h of daily listening) TMNMT
study indicated that training was more effective in the
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case of tinnitus frequencies ≤ 8 kHz compared to tin-
nitus frequencies > 8 kHz [13]. This was partially ex-
plained by the lower musical energy content in the
frequency region above 8 kHz. Furthermore, it became
obvious that to obtain more stable effects, a longer
period of training might be necessary [18]. However,
effects of TMNMT have already been demonstrated
after 3 days of training using a notch width of half an
octave [19–21]. A further methodological modification
of TMNMT was suggested by Stein et al. [20, 22], who
investigated the role of the notch edges. By increasing
spectral energy contrasts of the notch edges relative to
the frequency region outside of the notch, the authors
succeeded in further boosting the effect of lateral
inhibition. However, with the exception of the first
TMNMT study, none of the studies included a placebo
group, stressing the need for further evaluation and
replication. Based on the findings of those previous
studies, we have integrated our knowledge in order to
maximize the efficacy of TMNMT. Expanding on our
previous work, the present study includes equalization
of the music energy spectrum, edge enhancement and
a ½ octave notch. With these potential improvements
in mind, we decided to evaluate a training duration of
3 months and included a 1-month follow-up to evalu-
ate the stability of the effects. This decision also aimed
to increase applicability of the training. Furthermore,
in order to include a broader population of tinnitus
sufferers and to increase the sample size of the study,
we loosened the study inclusion criteria compared to
all previous studies allowing more hearing loss, higher
age and higher tinnitus pitch frequency. TMNMT was
designed to both reduce the aversive subjective per-
ception of the tinnitus as well as lessen the general
distress associated with tinnitus.
Our hypotheses were (1) a reduction of tinnitus dis-
tress measured by the Tinnitus Handicap Questionnaire
(THQ) [23] and the mean score of the VAS to be super-
ior in the treatment group compared to the placebo
group and (2) a larger decrease in tinnitus related dis-
tress in the Tinnitus Questionnaire (TQ) [24], the
Tinnitus Handicap Inventory (THI) [25] and each indi-
vidual VAS subscale (i.e., tinnitus loudness, annoyance,
handicap and distress) for the group, which received
TMNMT compared to the placebo group. In order to
promote transparency concerning our methods and out-
come measures, we published a protocol to this study
[26] in advance of the trial. The preparation, execution
and reporting of this study was done in accordance with
the CONSORT statement [27].
Methods
Trial design
The clinical trial design is graphically presented in Fig. 1.
This was a stratified (with balanced randomization [1:1]),
double blind, placebo-controlled, parallel-group study
conducted at the Institute for Biomagnetism and Biosigna-
lanalysis of the University of Muenster, Germany. Partici-
pants were recruited through an entry examination as
described herein. We invited subjects meeting the study
criteria after the entry examination for the baseline meas-
urement. We informed them about the clinical trial and
instructed them how to perform tinnitus pitch matching
Fig. 1 Illustration of the trial design
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during the following week (cf. assessment of the tinnitus
frequency). On a third (pre) date, 2 weeks later, partici-
pants were finally selected for the trial. The decision
was based on the outcome of the pitch-matching task.
We then provided participants with either tailor-made
notched music (TMNM) or placebo treatment for 3
months. Participants completed primary and secondary
outcome measures at baseline, initially before treatment
started (pre), at the end of the treatment (post) and at
1-month follow-up. Trend measurements consisted of
the primary outcome measures.
Participants
We recruited participants by means of advertisements in
local newspapers, the homepage of the Institute, the
homepage of the Faculty of Medicine of the University of
Münster and by the distribution of flyers to local Ear, Nose
and Throat (ENT) physicians. Potential participants were
asked to answer a questionnaire covering items like the
characteristics, duration, onset, possible cause, and treat-
ment of the tinnitus as well as pre-existing illnesses,
hyperacusis, current medication and drug consumption.
Depending on the results of the questionnaire, potential
participants were scheduled for a multidisciplinary entry
investigation in the ENT department of the University
Hospital of Münster. This procedure lasted approximately
2 h. It started with a screening by a psychologist, who
explored the occurrence, development, and treatment of
tinnitus as well as the criteria already specified in the
questionnaire described above. Furthermore, tinnitus-
related distress was assessed by means of standardized
questionnaires (THQ, THI, and VAS). Psychological as-
sessment was additionally supported by psychometric data
using a depression scale (Allgemeine Depressionsskala –
Langfassung, ADS-L) [28] and the Symptom Checklist to
capture general psychological distress (SCL-90-R) [29].
After psychological assessment, an ENT physician per-
formed a physical examination of the ear. Additionally, we
measured hearing thresholds of all potential participants
via an audiometric procedure using a clinical audiometer
(Type Madsen Astera, Denmark) that is able to operate in
an extended frequency range up to 16 kHz.
The participants recruited for the clinical trial had to
meet the following inclusion criteria:
1. (i) Chronic (≥3 months), tonal (i.e. beep- or whistle-
like) tinnitus with (ii) dominant tinnitus frequencies
between 1 and 12 kHz, and (iii) without hearing loss
above 70 dB HL in the frequency ranges of one half
octave above and below the tinnitus frequency. In
the case of bilateral tinnitus, the dominant tinnitus
frequency should not differ between ears according
to participants’ reports.
2. Aged between 18 and 70 years.
3. No report of severe chronic or acute mental or
neurological disorders (e.g. depression, amnesia,
dementia, epilepsy, etc.), which could result in
major difficulties maintaining motivational
compliance, the ability to follow instructions, or
to participate in the training.
4. No acute otological diseases.
5. No current consumption of illegal drugs or current
consumption of alcohol above the limit
recommended by the World Health Organization.
6. No other current tinnitus therapies or other
therapies that might interfere with this trial, and no
participation in another clinical trial.
7. Written informed consent to participate in the trial.
Participants were declared as “dropouts”, if they
indicated that they did not want to continue the
TMNMT. If tinnitus sufferers experienced a strong in-
crease of tinnitus loudness or started to hear an add-
itional tone after they listened to the music for at least
8 weeks, we advised them to stop their participation in
the training. Nevertheless, we asked participants who
stopped performing the training to continue complet-
ing questionnaires.
The ethical aspects of this clinical trial were reviewed
by an independent Institutional Review Board (Ethical
Commission of the University of Münster), and ethical
approval was obtained before the trial began (AZ: 2011–
109-f-S). In addition, participants in the trial were fully
informed about the nature, benefits, and potential dan-
gers of the trial as well as alternative treatment options
in accordance to the Good Clinical Practice Guidelines.
All participants signed an informed consent form before
they were enrolled in the study. They were informed that
if the treatment were effective and superior to placebo,
the participants of the placebo group would be provided
with the target treatment after completion of the trial.
Interventions
The intervention was conducted according to one of two
protocols: (i) target (fixed notch-TMNMT) condition or
(ii) placebo (moving notch) condition, described below.
In both conditions, participants received a mobile
device, which allowed them to perform the music train-
ing at home. Participants provided their favorite music
(10 CDs), which was then imported into the music
library of the mobile device and then modified in “real-
time” on the device in several successive steps described
below. To perform the necessary modification of the
music, software for an iOS application (App) has been
developed. The parameters for each condition could
be entered via a graphical user interface of the App.
The music was modified identically for both ears, and
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participants were supplied with closed headphones
(model: Sennheiser HD 201).
Target condition
In the target condition, the frequency band centered at
the individual tinnitus frequency of each participant was
removed from the music energy spectrum in three steps:
First, the energy spectrum of the music was “equalized”,
i.e. the amplitude of the music frequency spectrum in
the low and high frequency range was equalized by re-
distribution of energy from low to high frequency
ranges. This was intended to guarantee an equal amount
of spectral power below and above the frequency area
suppressed by the notch filter. Second, a frequency band
of ½ octave width centered at the individual tinnitus fre-
quency was removed from the music energy spectrum.
Third, the edge frequency bands of the notch were amp-
lified using a width of 3/8 octaves on each side of the
notch by 20 dB [20]. All three procedures aimed to in-
crease the lateral inhibition effect within the notch area
corresponding to the tinnitus frequency (cf. Fig. 2).
Control (Placebo) Condition
In the placebo condition, a moving notch filter with the
same bandwidth as in the target condition was applied.
The moving filter randomly selected a frequency band.
After 5 s of filtering, the center frequency of the filter
randomly jumped either 1/18 octave up or down and
continued jumping in the same direction every 5 s until
its lower or higher edge reached a predefined border at
which point it changed direction.
Assessment of the tinnitus frequency
To achieve an appropriate estimate of the tinnitus
frequency for the TMNMT, we adapted a recursive two-
interval forced choice estimation of the tinnitus fre-
quency [30, 31]. This method has been shown to
produce reliable results compared to the clinical audi-
ometry testing procedure, but it can be performed by
the participants themselves using the App and in one
third of the time [32]. Additionally, the procedure
allowed for the analysis of the variability of an individual
pitch matching session. For this procedure, the fre-
quency range (1 to 16 kHz) was bisected into two
equally large subintervals. For both the low and the high
frequency subinterval, the participant had to choose
whether the tinnitus was more similar to its lower or
higher frequency end. Depending on the outcome, bisec-
tion and two-interval forced-choice testing was reapplied
to the low subinterval, the high subinterval, or a new
middle interval that was bound by the midpoints of the
low and the high subinterval [30, 31]. Prior to testing,
the left or right ear was selected. Loudness of the test
tones was adjusted individually by participants to match
the tinnitus loudness and this value was saved by the
App. A two-alternative forced-choice octave confusion
test completed the testing. All choices made by partici-
pants were saved in an ASCII table file. Participants per-
formed the pitch-matching test at home twice a day for
5 days. To achieve an estimate for the tinnitus frequency
as the final tinnitus frequency for the treatment, fre-
quencies were transformed into Cent and the arithmetic
mean of the ten measurements was calculated. To esti-
mate how the values of the ten pitch measurements var-
ied within one participant; the standard deviation was
calculated for each participant.
Instructions for participants during TMNMT
Participants were instructed to listen to their individually
modified music for two successive hours per day for
12 weeks (168 h of TMNMT in total). They were
instructed to listen to the music attentively in a quiet
surrounding at home with comfortable loudness. They
were allowed to read, surf the internet or do other relax-
ing activities. Any cognitive or attention demanding task,
such as working or learning, were to be avoided. Add-
itionally, participants were instructed to avoid sound
distractions by other sound sources during TMNMT.
Outcomes
The primary efficacy endpoints in our study were at the
end of the training after 3 months of music training
(post) compared to pre measurement. The main out-
come domains were subjective tinnitus perception and
tinnitus distress.
Tinnitus perception is often measured subjectively via
VAS. The reliability of those scales in tinnitus is consid-
ered as good [33], though there is a lack of studies evalu-
ating VAS in tinnitus. To interpret the change in VAS,
Adamchic, and Langguth [33] have done a psychometric
evaluation, which has identified a minimally clinically
Fig. 2 Schematic illustration of music spectrum modification
(target condition). While music normally has less energy in the
lower frequencies (light blue bars), TMNM is equalized. A frequency
band of ½-octvae around the individual tinnitus frequency is
removed from the energy spectrum of the music. The frequencies
at the edge of the notch are enhanced
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important difference (MCID). To measure tinnitus re-
lated distress, a wide variety of questionnaires exists.
The most common ones are the TQ, the THQ and the
THI. All of those questionnaires define tinnitus handicap
and distress in different ways using different theoretical
concepts [34]. Besides ensuring construct validity, ques-
tionnaires as outcome measures should also be change-
sensitive to detect treatment responses. Unfortunately,
the authors of many tinnitus questionnaires do not pro-
vide grading systems or describe an MCID. For the TQ,
a grading system exists [35], which identifies an MCID
of five score points. For the THQ, an MCID of 21 score
points was reported [36] and for the THI, seven score
points have been suggested as an MCID [37]. Our choice
of outcome measures for the current study was moti-
vated by psychometric quality and change-sensitivity in
particular. Furthermore, we wanted to meet current rec-
ommendations for questionnaires in tinnitus studies [38]
and to use measures that were used in the previous
TMNMT studies to achieve comparability between the
studies. Therefore, we focused on THQ and VAS as pri-
mary outcome variables.
Primary outcome measures
(i) Tinnitus-related distress was assessed with the THQ.
For statistical analyses, we used the total score.
(ii)VAS total score. Participants rated their tinnitus
loudness, annoyance, awareness and handicap on
separate VAS (scale from 0 to 100). The mean score
from these four scales was used as the total score.
Secondary outcome measures
The German version of the Tinnitus Questionnaire was
used as a secondary outcome measure. Furthermore, the
emotional and cognitive distress subscale of the THQ
and the subscales of the VAS were analyzed.
Additional data
The time that was spent listening to TMNM was doc-
umented on a daily basis. Participants sent the data to
the study conductors via email once a week. To allow
further sub-group and covariate analyses, we collected
the following data: ADS-L, SCL-90-R, German Hyperacusis
Questionnaire (Geräuschüberempfindlichkeits-Fragebogen,
GÜF), subjective average listening duration and enjoyment
of conventional music prior to study enrollment, VAS
measuring different aspects of listening to TMNM during
the study (enjoyment, relaxation, attention to the music),
subjective experience with TMNMT (improvement of
tinnitus, recommendation of TMNMT) and side effects
during and after the training (open answer format). After
they had completed the training, participants were asked to
rate how effectively they had experienced the training on a
five point Clinical Global Impression scale (CGI; cf. [28])
ranking from “very much improved” to “very much wors-
ened”. Furthermore, they were asked to guess to which
group they had belonged.
Sample size
We performed a priori power calculations to estimate an
adequate sample size to find meaningful clinical changes
in our outcome variables. The calculations were per-
formed using G*Power 3.1.5 [39]. The estimation of the
expected effect size was based on an approximation rule
of thumb about the minimal clinically important differ-
ences proposed by Norman, Sloan, and Wyrwich [40]. In
their systematic review, they found that the threshold to
determine a clinically relevant change in health-related
questionnaires was approximately 0.5 standard deviations.
This corresponds to a standardized effect size of d = 0.5,
which can be interpreted as a medium effect [39]. The
conventions for effect sizes of repeated measures ANO-
VAs were defined by Cohen [41] as f = 0.1, f = 0.25 and f =
0.4 for small, medium and large effects, respectively. Thus,
we chose a medium effect size of f = 0.25 for our power
analysis to assure that we were able to detect the assumed
MCID. We planned to achieve a power of .90 for test-
ing the interaction effect Session (pre, post) x Group
(placebo, treatment) (5 % significance level). The cor-
relation between the two repeated measures was set to
r = 0. Note that this reflects a conservative approxima-
tion and any correlation larger than r = 0 would have
reduced the required amount of participants. These cal-
culations resulted in a sample size of n = 88. To take
dropouts into account, the final sample size was set to
n = 100, i.e. 50 participants per group.
Interim analyses and stopping rule
In order to rule out adverse effects of the treatment, an
interim analysis was conducted after 50 % of the partici-
pants completed the training (post measurement). For
this purpose, data was unblinded by an external person
and stored in a way that no inference to the single par-
ticipant could be made (e.g. without age, gender, hear-
ing loss, etc., only analysis relevant data). In case of a
significant interaction between Session and Group con-
cerning primary outcome measures revealing a negative
effect for the treatment group, the trial would have
been stopped.
Randomization and allocation
We included 100 participants with tonal tinnitus in two
study arms:
(i) Target group, 50 participants with tonal tinnitus
obtaining TMNMT.
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(ii) Placebo group, 50 participants with tonal tinnitus
obtaining placebo treatment.
The allocation to the two groups was done using
stratified randomization. Stratification is an appropriate
allocation method for improving power in small trials
(<400 participants) and preventing type 1 errors [42].
We used a minimum number of strata to improve statis-
tical efficiency, since this allows the assignment of an
equal number of participants to each group and assures
an equal distribution of the stratification factor between
groups [42]. We chose the variables age (<51 or > =
51 years) and hearing loss (<40 dB or > = 40 dB) [43, 44]
as stratification categories to keep the number of strata
minimal but include the two variables most likely to in-
fluence the treatment outcome. This resulted in four
strata: 1) age below 51 years and less than 40 dB hearing
loss, 2) age below 51 years and equal or more than 40 dB
hearing loss, 3) age equal or above 51 years and less than
40 dB hearing loss, 4) age equal or above 51 years and
equal or more than 40 dB hearing loss. Within each
stratum, a blocked randomization (block size = 4) was per-
formed using a computer generated randomization list.
To ensure that study results were not confounded by an-
ticipation or expectation, participants and investigators
remained blind to the allocation (double blind).
Blinding
An external person not involved in the Clinical Trial
was responsible for the allocation of each participant to
one of the two groups (treatment or placebo), and the
App was set up accordingly by a researcher who had
no contact with the corresponding participant. The
allocation of a participant to the target or the placebo
group was realized within the App through the appli-
cation of appropriate settings. Afterwards, the App
was password-locked to disable further changes and
reading of the settings.
Statistical methods
The respective hypotheses were formulated as one-sided
as proposed by Owen [45]. For p- values which point in
the opposite direction, the transformation 1-p/2 was
used. To assess the effect of TMNMT, we conducted an
intention-to-treat analysis with the data of all partici-
pants that were assigned to the treatment or to the pla-
cebo group. In anticipation of dropouts and missing
data, we chose a likelihood-based mixed-effects model
for repeated measures analysis as the primary analysis
[46, 47]. The model was implemented using the func-
tion lmer in R’s lme4 library [48]. Here, Subject was set
as a random effect and the factors Session (pre vs. post)
and Group (treatment vs. placebo) were defined as fixed
effects. Additionally, an analysis with complete cases,
i.e. without dropouts (“per protocol analysis”), was con-
ducted. This was implemented by means of a mixed
model repeated measures analysis of variances (ANO-
VAs) for primary and secondary outcome variables with
the within subject factor Session (pre vs. post) and the
between subject factor Group (placebo vs. treatment).
As described in the previous section, all outcome mea-
sures were assessed in a follow-up measurement 1
month after TMNMT cessation. To evaluate the time
course of the effect of TMNMT, an additional mixed
model ANOVA for repeated measures was conducted
including the follow-up measurement. This was done
with all primary and secondary outcome measures with
the factors Session (pre vs. post vs. follow-up) and
Group (placebo vs. treatment). If the sphericity assump-
tion was violated in any comparison, Greenhouse-
Geisser correction was applied to the data.
Additional analyses
For all significant results, an estimate for the effect size
was calculated. Here, we used a variant of Cohen’s d,
which was recommended by Morris [49] to compare ef-
fects in the treatment group to those in the control group,
which is based on pooled pretest standard deviations.
To examine the influence of additional variables on the
change in the primary outcome variables, we conducted
several univariate analyses of covariance (ANCOVAs). As
dependent variables, we used the change values of the pri-
mary outcome variables (post – pre) which were com-
pared between the two groups. The change value was
used, to facilitate the interpretation of the results. The
following variables were introduced in the ANCOVA as
covariates: listening times, hearing loss, tinnitus fre-
quency, standard deviation of tinnitus frequency mea-
surements for each subject (tinnitus pitch SD) and age.
Furthermore, we assessed the reliability of our two
primary outcome variables by calculating the correl-
ation coefficient between baseline and pre-training
measurement. For the mean VAS value, we found a
non-satisfactory low correlation between the baseline
and pre-training measurement. Hence we used a latent
change score analysis [50] to analyze the change in the
VAS total score in more detail. In this approach,
multiple-group structural equation modeling (SEM)
was used to estimate a latent, error-free factor that
represents group-specific change. This modeling ap-
proach is possible even in smaller samples as long as
high communality is given [51].
Results
Participant flow
An overview of the participant flow is given in Fig. 3. In
total, 195 patients were screened for the study. From
these participants, 37 did not meet the study criteria
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while 58 declined to participate in the study. The main
reasons for screening failure were hearing loss (27 %)
and tinnitus pitch (27 %). The main reason for partici-
pants to decline to take part in the study was a lack of
time (50 %). Finally, 100 participants were included and
randomly assigned to either treatment (n = 50) or pla-
cebo (n = 50) group. A total of 83 participants completed
the study: 43 in the placebo group and 40 in the treat-
ment group. The detailed numbers of analyzed partici-
pants per statistical analysis is shown in Table 1. The
most frequent reasons for discontinuation in both
groups were adverse effects on the tinnitus (31 %), per-
ceived quality of the music (25 %) and that the TMNMT
was experienced as too time consuming (25 %). The re-
cruitment of the participants took place between July
2013 and June 2014, and the follow-up period of the trial
was finished in October 2014. The interim analysis was
conducted in May 2014 when 44 participants had fin-
ished the 3 months on TMNMT or placebo interven-
tion. As there was no significant interaction between
group and primary outcome measures revealing a negative
effect for the treatment group, the trial was continued.
Baseline data
In the complete sample, the age of the participants was
between 21 and 68 years (M = 47.5, SD = 10.81) with
about one third (33 %) being female. The hearing loss
ranged between 0 and 70 dB. 20 % of the subjects
showed no clinically relevant hearing loss (<20 dB) while
20 % had a mild (20–40 dB) and 38 % a moderate (>40–
70 dB) hearing loss. Table 2 shows the demographic and
clinical characteristics at the baseline measurement for
treatment and placebo group separately.
Both groups were comparable in terms of demo-
graphic characteristics and in the psychoacoustic mea-
surements. Concerning the values in the primary and
secondary outcome measures, groups did differ signifi-
cantly only in the score of the TQ when all participants
were included in the comparison. Note, however, that
for the analysis of the secondary outcomes, we excluded
Fig. 3 Participant Flow
Table 1 Number of participants analyzed for each analysis
individually
Treatment Placebo
Primary outcome measures (pre vs. post)
THQ total score 39a 43
VAS total score 40 43
Secondary outcome measures (pre vs. post)
THI 40 43
TQ 40 43
Primary outcome measures (pre vs. post vs. follow-up)
THQ total score 37 41
VAS total score 37 41
Secondary outcome measures (pre vs. post vs. follow-up)
THI 37 41
TQ 37 41
aOne participant forgot to answer this questionnaire
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the participants, who had dropped out of the interven-
tion. Within this sample, we did not find any significant
difference between the two groups in any outcome
measure (all p > .1).
Numbers analyzed
Outcomes and estimations
Intention – to –treat analysis
The likelihood-based mixed effects model for repeated
measures with Subject defined as the random effect and
the factors Session (pre vs. post) and Group (treatment
vs. placebo) as fixed effects was calculated for primary
outcome measures of all participants, which took part in
the study, included. There were no significant effects for
both primary outcome measures (see Table 3.)
Analysis per protocol – outcomes at post-intervention
Primary outcome measures The mixed model ANOVA,
which was run on a sample without dropouts, with the
within subjects factor Session (pre vs. post TMNM ex-
posure) and the between subjects factor Group (treat-
ment vs. placebo) showed neither a significant main
effect for the factor Session, nor for the interaction effect
Group for THQ or VAS total scores (see Table 4).
Secondary outcome measures The mixed model
ANOVA with the within subjects factor Session (pre vs.
post) and the between subjects factor Group (treatment
vs. placebo) showed a significant interaction effect Ses-
sion x Group for the TQ, F (1, 81) = 4.075, p = .047
(two-sided), ηp
2 = .048, d = .182. This interaction effect
revealed a reduction of TQ scores for the placebo
group (pre: M TQ score = 23.56, SD = 13.56; post: M
TQ score = 22.61, SD = 13.02), while TQ scores for the
Table 2 Demographic and clinical characteristic at baseline
Treatment Placebo p-value
Mean (SD) Mean (SD)
Number 50 50
Age (years) 47.68 (9.94) 47.13 (11.70) .737
Gender (f/m) 17/33 16/34 .834
Hearing loss (dB)a 41.10 (20.26) 44.60 (21.54) .405
Tinnitus frequency (Hz)b 5406 (1731) 5458 (1519) .921
tinnitus pitch SD (Hz)b 1341 (1202) 1333 (1181) .855
Time since tinnitus onset (years) 7.03 (7.25) 8.95 (6.80) .175
THQ total score 24.95 (16.92) 28.51 (16.41) .288
THQ emotional and cognitive distress 20.95 (19.61) 22.85 (20.20) .635
VAS total score 42.83 (21.71) 44.71 (19.28) .647
VAS loudness 50.70 (23.19) 48.86 (22.23) .686
VAS handicap 28.58 (22.26) 31.36 (22.30) .534
VAS annoyance 39.70 (26.18) 40.32 (22.27) .899
VAS awareness 52.32 (24.58) 58.30 (21.57) .199
THI 24.10 (14.96) 26.96 (16.92) .373
TQ 19.12 (10,62) 25.28 (13.82) .014
ADSL 7.80 (6.29) 9.38 (7.27) .248
SCL-90-R 0.29 (0.28) 0.36 (0.34) .218
GüF 8.62 (5.59) 10.58 (7.43) .139
m=male, f = female, Hz = Hertz, dB = decibel, Tinnitus pitch SD = standard deviation of ten tinnitus pitch measurements before training
amaximum hearing loss in a frequency range ½ of an octave above and below the individual tinnitus frequency; bCent values retransformed into Hz to allow
better interpretation




Session 90.14 −0.288 .774
Session x Group 90.77 −1.127 .869
VAS total score
Session 88.52 −0.002 .999
Session x Group 88.85 0.280 .390
Stein et al. BMC Neurology  (2016) 16:38 Page 9 of 17
treatment group increased after TMNMT (pre: M TQ
scores = 19.85, SD = 10.75; post: M = 22.33, SD = 13.96;
see also Fig. 4). However, post-hoc analysis using
paired t-tests did not reveal significant differences be-
tween pre and post measures for each group individu-
ally (placebo group: t (42) = 1.137, p = .262; treatment
group: t (39) = −1.636, p = .110). Furthermore, a sig-
nificant main effect for the factor Session was found
for the VAS subscale awareness revealing an overall
reduction of VAS ratings for both groups (pre: M VAS
awareness ratings = 56.63, SD = 22.80; post: M VAS
awareness ratings = 50.10, SD = 25.65), F (1, 81) =
8.612, p = .004, ηp
2 = .096. All other comparisons were
not significant (see Table 5).
Analysis per protocol – outcomes at follow-up
Primary outcome measures We calculated an additional
mixed model ANOVA with the within subjects factor
Session (pre vs. post vs. follow-up) and the between subjects
factor Group (treatment vs. placebo). Again, we found no
significant effects for the primary outcome measures THQ
and VAS total score (see Table 6). Since no hypotheses for
follow-up measurements were formulated in the protocol,
the respective p-values are reported as two-sided.
Secondary outcome measures For the secondary
outcome measures, we found a significant interaction ef-
fect Session x Group for VAS loudness ratings, F (1.64,
124.95) = 4.262, p = .022, ηp
2 = .053, d = .266, revealing a
reduction of tinnitus loudness in the treatment group
(see Fig. 5). We calculated post-hoc tests using repeated
measures ANOVA with the between subjects factor Ses-
sion (pre, post, follow-up) for each group individually
which revealed a reduction of tinnitus loudness in the
treatment group (pre: M VAS loudness ratings = 53.46,
SD = 21.74; post: M VAS loudness ratings = 47.24, SD =
23.80; follow-up: M VAS loudness ratings = 45.14, SD =
24.45), F (1.58, 56.87) = 4.014, p = .032, ηp
2 = .10; while
there was no main effect of Session for the control group
(pre: M VAS loudness ratings = 46.15, SD = 21.89; post:
M VAS loudness ratings = 47.00, SD = 24.16; follow-up:
M VAS loudness ratings = 48.49, SD = 23.86), F (1.69,
67.76) = 0.576, p = .537, ηp
2 = .01. Furthermore, there was
a significant main effect Session for VAS awareness rat-
ings, F (1.56, 118.86) = 6.579, p = .004, ηp
2 = .080, revealing
an overall decrease of tinnitus awareness ratings after
TMNM exposure (pre: M VAS awareness ratings = 56.74,
SD = 22.84; post: M VAS awareness ratings = 50.10, SD =
26.00; follow-up: M VAS awareness ratings = 49.62, SD =




To exclude possible influences of third variables, we
calculated univariate ANCOVAs for the difference
values (post – pre TMNM exposure) of the primary
outcome measures. Here, we found a significant
covariance between listening times total and VAS total
Table 4 Mixed model ANOVA for primary outcome measures (pre vs. post)
Df (numerator, denominator) F-statistic p-value ηp
2
THQ total score
Session 1, 80 0.040 .842 .001
Session x Group 1, 80 0.678 .794 .008
VAS total score
Session 1, 81 3.050 .085 .036
Session x Group 1, 81 1.494 .113 .018
Fig. 4 Interaction effect of Session x Group for mean TQ scores.
Ns = not significant. * = p < .05
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change values, F (1, 68) = 2.036, p = .019, ηp
2 = .079.
However, treatment and placebo group did not differ
in VAS total change values after correction for the in-
fluence of the factor listening times total, F (1, 68) =
1.666, p = .201. No other comparisons showed signifi-
cant effects, as described in Table 8.
Structural Equation Model for VAS total values
Since VAS scales showed a low test-retest reliability
between both measurements before TMNM exposure
(r = .67), we performed a latent change score analysis.
In this approach, a SEM for both treatment and con-
trol groups with a number of constraints was specified
(see [50], Fig. 3 for a similar model). First, the model
included a pre-intervention and a post-intervention
factor based on the 4 VAS items investigated here.
The constraints with respect to these factors were that
(a) all factor loadings had to be identical for pre-
intervention and post-intervention factors as well as
(b) for both groups, (c) all residual correlations be-
tween pre-intervention and post-intervention items
were equal between groups, and (d) the path from pre-
intervention to post-intervention factor was fixed to 1 for
identification purposes [52]. Furthermore, a latent change
factor was included, representing the difference between
pre and post. This factor was identified by constraining its
path to the post-intervention factor to 1. Finally, latent
means of the pre-intervention and post-intervention
Table 5 Mixed model ANOVA for secondary outcome measures (pre vs. post)
df (numerator, denominator) F-statistic p-value ηp
2
THI
Session 1, 81 0.076 .783 .001
Session x Group 1, 81 0.049 .588 .001
TQ
Session 1, 81 0.803 .373 .010
Session x Group 1, 81 4.075 .977* .048
THQ factor 1
Session 1, 80 1.009 .318 .012
Session x Group 1, 80 0.973 .837 .012
VAS loudness
Session 1, 81 2.293 .134 .028
Session x Group 1, 81 2.369 .064 .028
VAS annoyance
Session 1, 81 0.441 .508 .005
Session x Group 1, 81 0.741 .196 .009
VAS awareness
Session 1, 81 8.612 .004*** .096
Session x Group 1, 81 0.288 .297 .004
VAS handicapping
Session 1, 81 0.120 .730 .001
Session x Group 1, 81 1.211 .137 .015
*Note, that this p-value would be considered as significant under a two sided testing (p = .047*)
*** = p < .01
Table 6 Mixed model ANOVA for primary outcome measures (pre vs. post vs. follow-up)
Effect df (numerator, denominator) F-statistic p-value ηp2
THQ total score
Session 1.72, 130.97a 0.666 .494 .009
Session x Group 1.72, 130.97a 1.183 .305 .023
VAS total score
Session 1.42, 108.24a 2.969 .073 .038
Session x Group 1.42, 108.24a 1.781 .182 .023
aGreenhouse-Geisser corrected
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factors were fixed to 0, and the mean of the change factor
was fixed to 0 in the control group.
Overall, model fit was good, χ2(60) = 76.62, p > .05,
CFI = .97. Critically, the mean of the latent change factor
in the treatment group differed significantly from 0,
standardized α = .238, p = .034 (one-sided). This result
implies that the VAS change in the treatment group was
significantly larger than in the control group. The stan-
dardized alpha may be interpreted similarly to an effect
size in that it reflects standardized mean differences be-
tween groups, i.e., there was a small but reliable reduc-
tion in VAS symptoms in the treatment group compared
to the control group. Note, that the test-retest reliability
of the THQ (r = .922) can be considered as satisfactory,
hence no a latent change score analysis was performed
for this primary outcome measure.
Subjective evaluation of treatment by participants
Music enjoyment A mixed model ANOVA with the
within subjects factor Session (pre vs. post) and the be-
tween subjects factor Group (treatment vs. placebo)
showed a significant main effect for the factor Session, F
(1, 81) = 59.37, p < .000, ηp
2 = .42. Thus, music enjoyment
during the last 4 weeks of the training was significantly
Fig. 5 Interaction effect of Session x Group for mean VAS loudness
ratings. ns = not significant. * = p < .05
Table 7 Mixed model ANOVA for secondary outcome measures (pre vs. post vs. follow-up)
Effect df (numerator, denominator) F-statistic p-value ηp
2
THI
Session 1.76, 133.98a 0.113 .870 .001
Session x Group 1.76, 133.98a 0.074 .908 .001
TQ
Session 1.57, 119.30a 0.758 .442 .010
Session x Group 1.57, 119.30a 2.459 .102 .031
THQ factor 1
Session 1.66, 126.37a 2.335 .110 .030
Session x Group 1.66, 126.37a 0.332 .678 .004
VAS loudness
Session 1.64, 124.95a 1.567 .215 .020
Session x Group 1.64, 124.95a 4.262 .022* .053
VAS annoyance
Session 1.51, 114.90a 1.205 .294 .016
Session x Group 1.51, 114.90a 1.440 .241 .019
VAS awareness
Session 1.56, 118.86a 6.579 .004** .080
Session x Group 1.56, 118.86a 0.041 .928 .001
VAS handicapping
Session 1.56, 118.71a 0.263 .714 .003
Session x Group 1.56, 118.71a 1.321 .267 .017
aGreenhouse-Geisser corrected
* = p < .05; ** = p < .01
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lower than general enjoyment of music before the train-
ing (pre: M VAS music enjoy ratings = 82.98, SD = 16.19;
post: M VAS music enjoy ratings = 63.86, SD = 21.18).
However, there was no interaction between groups, F (1,
81) = 1.51, p = .222.
Music listening times Due to technical problems, only
the data of 78 participants could be analyzed. On aver-
age, participants listened to the provided music on
71.56 days (SD = 16.36) for 115.29 min per day (SD =
16.01), which did not differ between groups (days
listened: t (76) = −0.52, p = .604; minutes per day lis-
tened: t (76) = 0.43, p = .669).
Subjective ratings of training benefit and judgement
of group allocation Table 9 depicts the subjective
ratings of training benefit of the CGI scale. The
judgments of group allocation by the participants are
shown in Table 10.
Harms
All participants were asked to report if they perceived
any harm or side effects after music exposure. Of all par-
ticipants who filled out a questionnaire asking for harms
(n = 92), the main harms reported were (1) a consistently
louder tinnitus (10.9 %), (2) the perception of an add-
itional sound (8.7 %), and (3) an increased awareness of
the tinnitus sound (6.5 %). However, harms did not differ
significantly between groups, χ2 (2) = 0.849, p = .654. In
total, 29.4 % of the participants reported some form of
harm, which is outlined in Table 11.
Discussion
This was the first randomized double blind clinical trial
on TMNMT. Overall, we did not find the hypothesized
reduction of tinnitus related distress and tinnitus
perception in the primary outcome measures, while in
Table 8 Mixed model ANCOVA for difference values (pre vs. post) of primary outcomes
df (numerator, denominator) F-statistic p-value ηp
2
Change VAS total
Hearing loss (HL_1/2oct)a 1, 80 0.944 .334 .012
Group (HL_1/2oct corrected) 1, 80 1.594 .217 .019
Listening times total (LTT) 1, 68 2.036 .019* .079
Group (LTT corrected) 1, 68 1.666 .201 .024
Tinnitus pitch SDb 1, 80 3.839 .054 .046
Group (tinnitus pitch SD corrected) 1, 80 1.406 .239 .017
Age 1, 80 0.167 .684 .002
Group (Age corrected) 1, 80 1.534 .219 .019
Change THQ total
Hearing loss (HL_1/2oct) 1, 79 1.196 .277 .015
Group (HL_1/2oct corrected) 1, 79 0.621 .433 .008
Listening times total (LTT) 1, 67 0.244 .623 .004
Group (LTT corrected) 1, 67 0.157 .693 .002
Tinnitus pitch SDb 1, 79 1.633 .205 .020
Group (tinnitus pitch SD corrected) 1, 79 0.752 .389 .009
Age 1, 79 .500 .481 .006
Group (Age corrected) 1, 79 .592 .444 .007
aHL_1/2oct = hearing loss in the range of ½ octave around the individual tinnitus frequency; bTinnitus pitch SD = standard deviation of ten tinnitus pitch measurements
before training
* = p < .05
Table 9 Subjective ratings of training benefit
Treatment Placebo Total
my tinnitus improved very much 1 0 1
my tinnitus improved a bit 9 5 14
my tinnitus did not change 16 30 46
my tinnitus worsened a bit 12 7 19
my tinnitus worsened very much 2 1 3
Table 10 Judgements of group allocation
Treatment Placebo Total
Judged placebo 38 31 69
Judged treatment 7 12 19
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secondary outcome measures a reduction of tinnitus
loudness in the treatment group was evident.
For the predefined primary outcome measures, TMNMT
was not superior to a placebo treatment directly after train-
ing cessation. Tinnitus distress scores and scores for the
subjective tinnitus perception remained at the same level
for the treatment and the placebo group. The results of the
intention-to-treat analysis did not differ indicating that
dropouts did not influence the results of the primary out-
come measures. Despite our previous reasoning, more time
may be necessary to create and stabilize more pronounced
effects of TMNMT on tonal tinnitus. In the study of
Okamoto et al. [17], TMNMT affected tinnitus loudness
after 6 months but it was shown to be superior to the pla-
cebo condition after 12 months. It is plausible that the
effect after three month was too small to be detected in be-
havioral measures directly after training cessation.
However, more recent studies suggest that short-term
changes in neurophysiological brain activity elicited
through TMNMT already begin to occur after three
days [19, 20]. Brain plasticity effects are often first ob-
served on a neural level and may only later manifest be-
haviorally [53]. Thus, TMNMT might need more time
to influence the subjective tinnitus perception.
Considering our secondary outcome measures, effects
differed between the placebo and the target group for
the TQ only. Contrary to our hypothesis, the placebo
group showed even lower scores in the TQ after the
training when compared to the treatment group. How-
ever, the effect did not reach significance when the
groups were analyzed separately. One explanation for
the contradicting effect in the TQ scores might be re-
gression to the mean, as the two groups differed slightly
(but not significantly) at the baseline measurement: The
placebo group had higher scores in the TQ than the
treatment group and therefore had a higher probability
to show a reduction at the second measurement point
(post training). Note, that for the TQ, the interaction
was no longer visible in the follow-up measurement. It
remains unclear, whether this small negative effect was
due to influence of TMNMT or a regression to the
mean. The effect of the reduction in tinnitus awareness
in both groups from pre to post measurement, and the
further decrease in the follow-up measurement, can be
explained by elevated tinnitus awareness at the start of
the trial. As participants expected changes in their tin-
nitus, they might have monitored their tinnitus more
carefully prior to and during the training. The reduction
towards the end of the trial can be seen as a returning to
a normal level.
In the follow-up analysis we found a significant reduc-
tion of tinnitus loudness in the treatment group, while
the scores in the placebo group reversed to baseline.
According to Adamchic & Langguth (2012) the change
in the loudness ratings of 6.22 points are not clinically
relevant as changes of visual analog scales need to be
greater than 10 points to be considered as an MCID.
However, despite the relatively small effect, this result
proved to be lasting. This can be explained by the fact
that one month after cessation of the training, any pla-
cebo effect had faded, while the effect of TMNMT was
persisting. Furthermore, this result underlines the above
statement that the behavioral effects of TMNMT need
more time than 3 months to evolve and stabilize. Given
the reliability calculations within our study, we added
the calculation of an SEM to our analysis. The calcula-
tion of an SEM resulted in a rather small effect size, but
hints towards a positive effect of TMNMT as compared
to placebo treatment in the post measurements for the
mean VAS ratings. The result of this analysis has to be
interpreted with care, as the analysis was not prevised in
our protocol and further research is needed to confirm
this preliminary data. Taken together with the reduction
of tinnitus loudness, which was found in the follow-up
measurement, we would conclude that 3 months of
TMNMT had a relatively small, but persistent influence
on the subjective tinnitus perception.
A considerable number of participants reported the
experience of adverse effects during the duration of the
trial. We do not know if the number of reported ad-
verse effects is comparable or equal to previous studies,
as none of the previous studies concerning TMNMT
has asked for adverse effects with an open question
item [17, 18, 54]. However, those adverse effects ap-
peared to be unspecific and not caused by TMNMT, as
they were evenly distributed between the two groups.
Therefore, the adverse effects that participants experi-
enced could be interpreted as general effects of atten-
tion towards the tinnitus due the participation in the
study. Furthermore the adverse effects might be general
symptoms associated with tinnitus that would have ap-
peared even without participating in the study. A moni-
toring group would have given more insight to this.
Table 11 Reported harms after tailor-made notched training
(post measurements)
Treatment Placebo Total
Number of participants with harms 12 15 27
Consistently louder 5 5 10
Additional sound 4 4 8
More aware of tinnitus sound 2 4 6
At times louder 2 2 4
Changes in sense of hearing 0 3 3
Tinnitus sound changes 0 3 3
Psychological stress 1 2 3
Other bodily changes 0 2 2
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How clear is the evidence of 3 months TMNMT as
treatment against tinnitus? The results of the current
study point in different directions: Directly after the train-
ing, we observed no significantly positive effect with the
proposed analysis. Even the reverse was true, as for one of
the secondary measurements of tinnitus distress, a nega-
tive development was found in the treatment group when
compared to the placebo group. This small effect, how-
ever, was not observable 1 month after training cessation.
On the other hand, a reduction in tinnitus loudness,
awareness, handicap and annoyance due to TMNMT was
found with more explorative analysis. This hint could be
strengthened by the observation of a reduction of tinnitus
loudness in the TMNMT group 1 month after training
cessation. Taken together, our results display a positive ef-
fect of three months of TMNMT on the subjective
tinnitus perception, especially concerning tinnitus loud-
ness. These results are in line with the previous placebo
controlled study of Okamoto et al. [17], which demon-
strated a positive effect of TMNMT on the VAS loudness
scale as well. Other studies of TMNMT had different
designs and training durations and used varying outcome
measures making it difficult to compare the results.
Okamoto et al. [17] used VAS and calculated relative
change values, Teismann et al. [13] used the THQ, the TQ
and VAS scales, but did not find effects for all measures at
all time points. Teismann et al. [54] found effects for the
THQ but not for the VAS. Stein et al. [19] as well as Stein
et al. [20] found effects in the VAS. So far, these studies
have been performed using smaller samples and most of
them did not have a placebo group to control the effects.
Considering the placebo controlled studies only, consist-
ent effects of TMNMT are observable for subjectively
perceived tinnitus loudness. Longer time of at least twelve
months [17] may be necessary to stabilize the positive
effects of TMNMT on tonal tinnitus.
Within the research on sound therapies, clinical trials
focusing on the effectiveness of a specific sound treatment
without any other combined strategy are rather seldom
[5]. Hence, this study offers valuable insights into the ef-
fectiveness of a specific sound therapy as a stand-alone
treatment against tinnitus. Analogously to previous stud-
ies on sound therapies, the significant effects we have ob-
tained after only 3 months of training are rather small,
however still persisting in the follow-up measurements
after 1 month. Therefore, it could be a goal to further im-
prove the effectiveness of TMNMTand to integrate it in a
more holistic approach of tinnitus treatment.
Limitations
Tinnitus-related distress was generally low in our sample,
even before the training. High levels of tinnitus distress
are often accompanied by mental disorders [55]. Through
our exclusion criterion regarding mental disorders like
depression, we might have likewise excluded participants
with higher distress levels. This could have led to a floor
effect, where an improvement was more difficult to detect.
On the other hand, mental disorders were an exclusion
criterion in all previous studies investigating TMNMT.
Therefore, it still remains unclear whether TMNMT
would be suitable for participants that are highly dis-
tressed by their tinnitus. Importantly, hearing loss, age
and tinnitus frequency criteria are factors, which differed
from previous TMNM studies. Yet, covariate analyses
with these factors did not show any influence on the re-
sults. Therefore, we conclude that differences between
this study and previous studies regarding those vari-
ables are negligible.
Another limitation is the psychometric quality of our
outcome measures. As mentioned above, not all out-
come measures were specifically developed to measure
change in clinical trials. A relatively new and well-
described questionnaire is the Tinnitus Functional Index
(TFI) [56]. This questionnaire differentiates between dif-
ferent domains of tinnitus distress and the authors pro-
vide a grading system and a MCID score to be used for
clinical interpretation [27]. Therefore, it appears to be a
measure that should be considered as an outcome meas-
ure in future clinical trials for tinnitus. However, when
our clinical trial was started, the evaluation of the TFI
was not completed nor was a German version available
and evaluated.
Conclusions
This is the first study on TMNMT that was planned and
conducted following the CONSORT statement standards
for clinical trials. The current work is one more step to-
wards a final evaluation of TMNMT. Already after 3
months the effect of training with TMNM is observable in
the most direct rating of tinnitus perception – the tinnitus
loudness, while more global measures of tinnitus distress
do not show relevant changes.
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